Mabpharm Past Earnings Performance

Past criteria checks 0/6

Mabpharm's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 34.8% per year.

Key information

-8.5%

Earnings growth rate

-0.5%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate34.8%
Return on equity-63.3%
Net Margin-272.9%
Next Earnings Update26 Mar 2024

Recent past performance updates

Recent updates

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Revenue & Expenses Breakdown
Beta

How Mabpharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2181 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2371-194131129
31 Mar 2364-202125139
31 Dec 2256-211119148
30 Sep 2243-237119163
30 Jun 2230-263119178
31 Mar 2257-278110221
31 Dec 2183-292100264
30 Sep 2182-28489243
30 Jun 2181-27679223
31 Mar 2141-23072172
31 Dec 200-18566120
30 Sep 205-16366128
30 Jun 2011-14166136
31 Mar 2012-17264135
31 Dec 1914-20363134
30 Sep 1916-20860128
30 Jun 1917-21257121
31 Mar 1921-16950105
31 Dec 1824-1254289
31 Dec 175-312522

Quality Earnings: 2181 is currently unprofitable.

Growing Profit Margin: 2181 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2181 is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.2%).


Return on Equity

High ROE: 2181 has a negative Return on Equity (-63.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.